The meeting focused on strategies to accelerate product development and introduction for HIV prevention and treatment, using Lenacapavir for PrEP as a case study. The discussion highlighted collaborative regulatory pathways such as EU Medicines for All (EUM4ALL) and WHO’s SRA Collaborative Registration Procedure (SRA-CRP), aiming to reduce time from approval to patient access.
25 November 2025
English
Slides on EU-M4all, SRA CRP and LEN for PrEP
- 2025-11-25-Understanding-EU-M4All_International-AIDS-Society-ILF.pdf (698.13 KB)
- SRA-CRP_WLAs_Nov-2025.pdf (2.02 MB)
- IAS-LEN-case-study_KG-24Nov2025_FINAL.pdf (772.94 KB)
Find out more about the work of the IAS